Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban in Subjects With Cancer Related Venous Thromboembolism
NCT02585713Phase 3Completed
- Sponsor
- Academic and Community Cancer Research United
- Start
- Nov 2015
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of apixaban in venous thromboembolism (VTE) (2 arms), sponsored by Academic and Community Cancer Research United. Primary endpoint: 6 Month Bleeding Rate. Started Nov 2015; status: completed.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT02585713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02585713.